Mankind Pharma IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 4326.36 Cr. The company is based in New Delhi and caters to Pharmaceutical sector. Axis Capital , IIFL Securities , Jefferies India , Kotak Mahindra Capital Company are the merchant bankers of Mankind Pharma IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 15th September 2022.
Mankind Pharma IPO posted revenues of ₹ 9037.09 crores and PAT of ₹ 1346.92 crores in FY23 on annualised basis.Financial results of Mankind Pharma IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Financials | Dec-22 | FY 22 | FY 21 | FY 20 | |
---|---|---|---|---|---|
Balance Sheet
|
|||||
Assets | 9.00 | 9.00 | 6.00 | 5073.29 | |
Net Worth | 7.00 | 6.00 | 4.00 | 3.00 | |
Total Debt | 167.93 | 868.03 | 234.53 | 126.92 | |
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
6.00
8.00 |
7.00 | 6.00 | 5.00 | |
EBITDA
EBITDA on annualised basis |
1493.60
1,991.47 |
2003.80 | 1659.70 | 1448.30 | |
PAT
PAT on annualised basis |
1.00
1.33 |
1.00 | 1.00 | 1.00 |
Mankind Pharma IPO PAT Margin is 16.67 % , ROCE (Return on Capital Employed) is 16.58 % as per latest financial. The below table shows Mankind Pharma IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
Particulars | Dec-22 | FY 22 | FY 21 | FY 20 |
---|---|---|---|---|
EBITDA Margin (%) | 24,893.33 | 28,625.71 | 27,661.67 | 28,966.00 |
PAT Margin (%) | 16.67 | 14.29 | 16.67 | 20.00 |
EPS (₹) | 24.87 | 35.78 | 31.59 | 25.72 |
ROE (%) | 14.29 | 16.67 | 25.00 | 33.33 |
ROCE (%) | 16.58 | 25.50 | 30.41 | 35.86 |
ROA (%) | 11.11 | 11.11 | 16.67 | 0.02 |
Debt to Equity | 23.99 | 144.67 | 58.63 | 42.31 |
The market Capitalisation of Mankind Pharma IPO is ₹ 43263.60 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Mankind Pharma IPO prospectus highlights an Return on Equity (ROE) of 14.29 % , Return on Assets (ROA) of 11.11 %, and an EBITDA Margin of 24,893.33 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Mankind Pharma IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Mankind Pharma IPO is ₹ 43263.60 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Mankind Pharma IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Mankind Pharma IPO reported revenue of ₹ 9037.09 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Mankind Pharma IPO provide insights into sales growth, market demand, and business scalability.
Mankind Pharma recorded an EBITDA of ₹ 1,991.47 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Mankind Pharma Profit After Tax (PAT) is ₹ 1.33 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Mankind Pharma operates in Pharmaceutical and Pharmaceutical Products With A Major Focus On Domestic Markets. The Issue is listed on BSE,NSE in May, 2023. Mankind Pharma IPO size was 4326.36 with Issue price of 1080.00 .
Merchant Banker(s) of Mankind Pharma IPO: Axis Capital Limited , IIFL Securities Limited , Jefferies India Private Limited , Kotak Mahindra Capital Company Limited
Mankind Pharma IPO subscription was 15.32 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Mankind Pharma IPO listed at a listing price of 1424.05 against the offer price of 1080.00.
The current market price of Mankind Pharma is 2303.50.
Why Us?